This poster, presented at WMS 2022, focuses on the safety and efficacy results of Study 041, a phase 3 placebo-controlled trial of ataluren for patients with nonsense mutation Duchenne muscular dystrophy (nmDMD)
This poster, presented at WMS 2022, shows findings from a registry study investigating the effects of a mutation-specific treatment for nonsense mutation Duchenne muscular dystrophy (nmDMD) on upper limb function
The best practice management and continuity of care in patients with Duchenne muscular dystrophy (DMD) was the focus of this symposium, presented at WMS 2022
This poster, presented at the 2021 virtual WMS Annual Congress, presents a comparison of ambulatory outcomes following treatment for nonsense mutation Duchenne muscular dystrophy (nmDMD) in a registry study and a Phase 3 clinical trial
Year
Therapy area
Type
Congress
Topic